The master switch for your reproductive system. The neuropeptide your hypothalamus uses to start puberty, run the menstrual cycle, and maintain testosterone production. Now in human trials for low desire and fertility issues.
The 30-second read
Kisspeptin is a naturally occurring neuropeptide that sits at the very top of the reproductive hormone cascade. It tells the hypothalamus to release GnRH, which tells the pituitary to release LH and FSH, which tell the gonads to make testosterone or estrogen. When kisspeptin signaling fails, puberty doesn't start. When it works, the rest of the system follows. Researchers, most notably Waljit Dhillo's group at Imperial College London, have been running human trials of synthetic kisspeptin for hypoactive sexual desire disorder, hypothalamic amenorrhea, fertility issues, and IVF stimulation. Results are promising. It's not yet FDA-approved for any consumer indication. This is real reproductive endocrinology, not a casual peptide.
Why this peptide is on people's radar
Kisspeptin's discovery as the master regulator of puberty was a genuine surprise in reproductive endocrinology. Researchers in the early 2000s, working with patients who had a particular form of delayed puberty (a condition called hypogonadotropic hypogonadism), traced the underlying problem to mutations in the KISS1R gene, a receptor whose ligand turned out to be a then-obscure peptide called kisspeptin. The mechanism became clear: kisspeptin acts on GnRH neurons in the hypothalamus, telling them when and how to fire. Without that signal, puberty doesn't happen. With it restored, it can.
That discovery launched a research program that's now in full swing. Waljit Dhillo and colleagues at Imperial College London have run human trials testing kisspeptin in: hypoactive sexual desire disorder (HSDD), hypothalamic amenorrhea (a condition where stress or low body weight shuts down menstruation), male hypogonadism, and as a stimulation agent in IVF. The IVF use case in particular has produced positive trial data, kisspeptin appears to drive an LH surge in IVF protocols with a much lower rate of ovarian hyperstimulation syndrome than current drugs.
Outside the formal trials, kisspeptin is starting to appear in research-peptide circles for libido and reproductive-axis support. Worth flagging up front: this is not a cosmetic peptide. Kisspeptin directly drives sex hormone production. Push doses too high and you can meaningfully shift endocrine function. The clinical trials are conducted by reproductive endocrinologists for good reason.
What people are usually trying to do with it
People exploring kisspeptin are usually focused on:
Restoring sexual desire in clinical hypoactive sexual desire disorder (HSDD)
Supporting return of menstrual cycles in hypothalamic amenorrhea (often related to stress or low body weight)
Supporting fertility, particularly in women with hypothalamic causes
Replacing standard IVF "trigger" injections with a more physiologic option
Restoring testosterone production where the cause is at the hypothalamic level
Adding a top-of-the-cascade option to a reproductive-hormone protocol
What the science actually shows
More rigorous human evidence than most non-FDA-approved peptides on this site, with a real ongoing development program. Plain-English summary:
HSDD in women
Imperial College London trials have reported that kisspeptin enhances sexual and emotional brain responses to sexual cues in women with HSDD. The effect is observed both behaviorally and on functional MRI imaging.1
Hypothalamic amenorrhea
Trials in women with hypothalamic amenorrhea have shown that kisspeptin can stimulate the GnRH-LH-FSH cascade and restore reproductive hormone signaling, potentially helping return of ovulation and menstrual cycles.2
IVF "trigger" use
One of the most clinically advanced applications. Trials of kisspeptin as the LH-surge trigger in IVF have shown effective ovulation triggering with markedly lower rates of ovarian hyperstimulation syndrome (OHSS) compared with standard hCG triggers.3
Male hypogonadism
Smaller trials in men with hypothalamic causes of low testosterone have shown that kisspeptin can stimulate LH release and testosterone production.4
What hasn't been demonstrated
FDA approval for any consumer indication. Sustained efficacy with chronic dosing in healthy adults using it for "libido enhancement." Safety in long-term use outside the clinical-trial protocols. That kisspeptin is a casual peptide for general libido or reproductive support, it isn't.
The honest read
What's solid:
The basic science, that kisspeptin is the master upstream regulator of the reproductive hormone axis, is among the better-established pieces of modern reproductive endocrinology. The Imperial College London trial program is rigorous, well-published, and producing real clinical signals across multiple indications.
What's still being worked out:
Optimal dosing for each indication. Whether the IVF-trigger use case will translate to FDA approval (looks promising, not guaranteed). Long-term safety in chronic use. The healthy-adult libido use case, there's much less evidence for that than for the clinical indications.
What's hyped beyond the evidence:
Treating kisspeptin as a libido peptide for casual use. The clinical trials are in patients with measurable reproductive dysfunction; using it as an enhancement in healthy adults rests on extrapolation. Push doses too high without supervision and you can produce meaningful endocrine effects you didn't intend. This is real reproductive endocrinology, clinical supervision matters.
Things to know if you're looking into it
How it's used in research: typically a subcutaneous injection or short IV infusion. Trial protocols vary widely, kisspeptin doses have spanned from 0.1 to 10 mcg/kg in different studies because researchers are still mapping the dose-response curve.
This is reproductive endocrinology, not a cosmetic peptide: kisspeptin directly drives LH/FSH and therefore testosterone and estrogen. Push doses too high and you can meaningfully shift hormone levels. Clinical supervision is strongly advised.
Regulatory status: not FDA-approved for any consumer indication. Active clinical-trial program by Imperial College London and others. The IVF-trigger use case is the most likely first clinical approval.
Different forms: "Kisspeptin-10" and "Kisspeptin-54" are the most common synthetic forms in research. Their pharmacokinetics differ and the doses aren't directly equivalent.
Reported tolerability: trial data has been generally favorable. The most common adverse events relate to dose-dependent endocrine effects rather than direct toxicity.
Healthcare provider involvement: essential. Anyone with reproductive hormone concerns serious enough to consider kisspeptin should be working with a clinician, ideally a reproductive endocrinologist.
Specific dosing protocols, mechanism, half-life, and trial detail: all in the "Want to go deeper?" section below.
Reconstitution & dose calculator
Active clinical research, not FDA-approved. Imperial College London trials use kisspeptin-54 via IV infusion (1 nmol/kg/h for 75 min in HSDD studies); research-peptide channels typically sell kisspeptin-10 for SubQ use. Same family, different molecule, different route — the dose math below covers the SubQ research-peptide form, not the IV trial protocol. Clinical use of kisspeptin is reproductive endocrinology, ideally supervised by a clinician with that specialty. This is an educational reference, not dosing guidance.
Suggested start
100 mcg/day
Lower end of community range
Common range
100–250 mcg/day
Once daily; some advanced protocols 2–3×
Max community dose
500 mcg/day
PCT-style protocols sometimes higher
Cycle
4–8 wks on
Then 2–4 weeks off
mL
Defaults give 2.5 mg/mL on both vials — standard 100 mcg dose lands at 4 units, 250 mcg at 10 units. The 10 mg vial uses 4 mL water; if your vial can't hold 4 mL, drop to 3 mL (3.33 mg/mL, slightly different unit numbers but still readable).
mcg
Subcutaneous injection. Most community protocols dose once in the morning to align with natural reproductive-hormone pulsatility. Some advanced protocols use 2–3 doses spaced 4–6 hours apart to mimic the pulsatile GnRH pattern more closely — the duration estimate below assumes once daily.
Above the typical community range. PCT-style protocols (post-cycle testosterone restart) sometimes use higher doses, but those operate outside the libido/HSDD use case the calculator targets. Doses above 500 mcg/day exit common community protocols without clear added benefit at the receptor level.
Concentration
2.5 mg/mL
Per dose
0.04 mL
4 units on insulin syringe
Doses per vial
~100
~100 days (~14.3 weeks) of daily dosing
When to stay put vs. adjust
Stay put at 100 mcg in the morning for the first 2 weeks. Kisspeptin acts upstream of the entire reproductive hormone cascade — the effect builds over weeks as LH/FSH/testosterone or estrogen levels respond, not in days. The marker to watch is whatever the underlying issue is (libido, menstrual return, hormonal labs); subjective day-to-day sensation isn't reliable at the upstream-signaling level.
Consider stepping to 200–250 mcg or adding a second daily dose only after at least two weeks at 100 mcg with clear tolerability and limited progress. The pulsatile-GnRH-mimicking case for splitting into 2–3 daily doses (spaced 4–6 hours apart) is mechanistically sound but adds practical burden — worth trying only if a single daily dose isn't moving the needle.
Don't go above 500 mcg/day for libido or HSDD-style use. PCT (post-cycle testosterone restart) protocols sometimes use higher doses, but those operate in a different context (recovering from a TRT or anabolic cycle) with different goals. Above 500 mcg, you're either in PCT territory or exiting common community protocols entirely.
Cycle off at the 4–8 week mark for 2–4 weeks. Continuous chronic stimulation of the reproductive axis isn't well-characterized in healthy adults, and the off-cycle helps prevent receptor desensitization. The body has its own kisspeptin signaling rhythm — sustained exogenous input may blunt the natural pattern over time.
Watch for mild flushing, occasional headache, or unusual changes in libido pattern. Trial data has been generally favorable for tolerability; serious adverse events have been infrequent. Most reported effects are dose-dependent and resolve quickly when the dose drops.
Track the underlying labs if you're treating a hormonal issue. Kisspeptin's whole mechanism is upstream of measurable hormones (LH, FSH, testosterone, estradiol). If you're using it for hypothalamic amenorrhea, fertility, or significant HSDD, the right framework is "did the downstream hormones move?" — and that requires actual lab work, not vibes.
The honest read. The basic science is among the better-established pieces of modern reproductive endocrinology, and the Imperial College London trial program is rigorous and producing real clinical signals. Most of that work uses kisspeptin-54 via IV infusion in clinical settings — what's available through research-peptide channels is typically kisspeptin-10 for SubQ use. Same receptor family, different molecule, different route. Dose extrapolation between the two is uncertain. The healthy-adult libido use case in particular is an inferential leap from the trials, which were done in patients with diagnosed HSDD or hypothalamic dysfunction. If you're a healthy adult using kisspeptin to "boost libido" rather than treat a measurable issue, the evidence supporting that use is much thinner than the marketing implies.
For educational and research purposes only. This is not medical advice. Kisspeptin is not FDA-approved for any consumer indication. Active clinical trials are underway, primarily through Imperial College London. Reproductive hormone interventions warrant clinical supervision, ideally by a reproductive endocrinologist. Consult a licensed healthcare provider before any health decision.
What people often ask
Will kisspeptin boost my libido?
The clinical trials in HSDD show effects on brain-level processing of sexual cues. Whether that translates into reliable libido enhancement in healthy adults without HSDD is much less established. The honest framing: it's a reproductive-axis drug, not a recreational libido booster.
How is it different from PT-141 / Bremelanotide?
Different mechanism entirely. PT-141 acts on melanocortin receptors in arousal-related brain regions. Kisspeptin acts on GnRH neurons in the hypothalamus and drives the entire reproductive hormone cascade. PT-141 is approved for HSDD on demand. Kisspeptin is investigational and works through a much more upstream pathway.
Could it help fertility?
The IVF-trigger trial data is encouraging. The hypothalamic-amenorrhea data is encouraging. For other fertility contexts (PCOS, age-related decline, unexplained infertility), the evidence is much thinner and the appropriate fertility evaluation should come first.
Will it raise my testosterone?
If your low testosterone is coming from a hypothalamic cause (low signal upstream), potentially yes. If it's coming from a primary testicular issue, kisspeptin can't help because the problem is downstream of where it acts. Proper endocrine evaluation matters.
Is it FDA-approved?
Not for any consumer indication as of May 2026. The most likely first FDA approval is for IVF-trigger use, based on the trial data showing reduced OHSS risk.
What's the difference between Kisspeptin-10 and Kisspeptin-54?
Different lengths. Both come from the same parent KISS1 gene product. Kisspeptin-54 is longer and has a longer half-life; Kisspeptin-10 is shorter, faster-acting, and the form most commonly used in clinical trials. They're not directly dose-equivalent.
Are there side effects?
Trial data shows generally favorable tolerability. The main consideration is dose-dependent endocrine effects, pushing the reproductive-hormone cascade too hard can produce changes you didn't intend, particularly with chronic dosing. Clinical supervision matters here in a way it doesn't for most cosmetic peptides.
FDA and regulatory status
Status as of May 5, 2026: Not FDA-approved for any consumer indication. Active clinical trial programs are underway, primarily through Imperial College London and partner institutions, evaluating kisspeptin in HSDD, hypothalamic amenorrhea, IVF-trigger use, and male hypogonadism. The IVF-trigger use case is the most clinically advanced and most likely candidate for first regulatory approval. Status updates land here when they happen.
Want to go deeper?
Mechanism, GnRH/LH/FSH cascade detail, dosing, the Imperial College London trial program, side effects, and references. Click to expand.
Background and discovery
Kisspeptin is a neuropeptide encoded by the KISS1 gene, originally identified in the 1990s as a tumor metastasis suppressor (the name "kisspeptin" combines "Kiss", for the gene's anti-metastatic role, with the city of Hershey, PA, where the gene was first characterized). The reproductive role was identified in the early 2000s, when researchers traced certain forms of hypogonadotropic hypogonadism (a condition where puberty fails to begin) to mutations in KISS1R (the kisspeptin receptor). That discovery established kisspeptin as the master upstream regulator of GnRH neurons and, by extension, the entire reproductive hormone axis.
Mechanism of action
The KISS1R / GnRH axis
Kisspeptin binds the KISS1R receptor (formerly known as GPR54) on GnRH neurons in the hypothalamus. KISS1R activation triggers GnRH release. GnRH acts on the anterior pituitary to release LH and FSH. LH and FSH act on the gonads (testes or ovaries) to drive testosterone or estrogen production. Kisspeptin sits at the very top of this cascade.
Pulsatile vs. continuous signaling
The reproductive system depends on pulsatile GnRH release. Kisspeptin protocols designed to maintain pulsatile signaling work differently from continuous-infusion protocols. This is a meaningful detail in trial design and clinical use.
Brain-level effects on desire and emotional response
Beyond direct hormone-cascade effects, kisspeptin appears to act on brain regions involved in sexual and emotional processing, observed both behaviorally and on functional MRI in HSDD trials. This broader CNS effect is one of the more interesting features of the peptide.
Forms. Kisspeptin-10 vs Kisspeptin-54
Both are bioactive fragments of the parent KISS1 gene product. Kisspeptin-54 is longer with a longer half-life; Kisspeptin-10 is the most-studied short form. Different studies use different forms, and the doses are not directly interchangeable.
Investigational dosing
Investigational only. Doses described below are from clinical trials and do not constitute prescribing recommendations.
Trial doses have spanned a wide range as researchers map the dose-response curve. Kisspeptin-10 doses in trials have ranged from approximately 0.1 to 10 mcg/kg, given as IV infusion or subcutaneous injection. Kisspeptin-54 doses are different (lower mcg ranges over longer durations because of the longer half-life). Specific protocols depend on the indication studied.
The Imperial College London trial program
Waljit Dhillo and colleagues at Imperial College London have led much of the modern kisspeptin clinical research. Their published trials cover:
HSDD in women: kisspeptin-10 enhanced sexual and emotional responses to sexual cues, both behaviorally and on functional MRI imaging.
Hypothalamic amenorrhea: kisspeptin restored LH/FSH signaling and supported recovery of menstrual function in some patients.
IVF trigger: kisspeptin-54 effectively triggered the LH surge needed for IVF egg maturation, with much lower OHSS rates than standard hCG triggers, a meaningful clinical safety benefit.
Male hypogonadism: kisspeptin stimulated LH release and testosterone in men with hypothalamic causes of low testosterone.
Side effects and safety profile
Reported in trials and small clinical experience:
Mild injection-site reactions (uncommon)
Transient warmth or flushing (uncommon)
Dose-dependent endocrine effects (the main consideration, pushing doses too high can shift testosterone, estrogen, or LH/FSH meaningfully)
OHSS risk in IVF context is reduced compared with hCG triggers (a known clinical advantage)
Long-term safety data outside the clinical-trial context is limited. Anyone with serious reproductive concerns should be working with a reproductive endocrinologist rather than self-administering.
References
Comninos AN, Demetriou L, Wall MB, et al. (2018). "Modulations of human resting brain connectivity by kisspeptin enhance sexual and emotional functions." JCI Insight, 3(20), e121958. PubMed
Jayasena CN, Abbara A, Veldhuis JD, et al. (2014). "Increasing LH pulsatility in women with hypothalamic amenorrhoea using intravenous infusion of Kisspeptin-54." J Clin Endocrinol Metab, 99(6), E953–E961. PubMed
Abbara A, Jayasena CN, Christopoulos G, et al. (2015). "Efficacy of Kisspeptin-54 to trigger oocyte maturation in women at high risk of ovarian hyperstimulation syndrome (OHSS) during in vitro fertilization (IVF) therapy." J Clin Endocrinol Metab, 100(9), 3322–3331. PubMed
George JT, Veldhuis JD, Tena-Sempere M, et al. (2013). "Exploring the pathophysiology of hypogonadism in men with type 2 diabetes: kisspeptin-10 stimulates serum testosterone and LH secretion." Eur J Endocrinol, 168(1), 33–43. PubMed
Skorupskaite K, George JT, Anderson RA. (2014). "The kisspeptin-GnRH pathway in human reproductive health and disease." Hum Reprod Update, 20(4), 485–500. PubMed
For educational and research purposes only. This is not medical advice. Kisspeptin is investigational, not FDA-approved as of May 2026, and acts directly on the reproductive hormone axis, clinical supervision is strongly advised. Consult a licensed healthcare provider, ideally a reproductive endocrinologist, before considering use. PeptideLibraryHub is independent and does not sell peptides or accept money from anyone who does.